

## Anton Pottegård

Professor, University of Southern Denmark  
Head of Research, Hospital Pharmacy, Odense University Hospital

Mobile phone: +45 28913340  
E-mail: apottegaard@health.sdu.dk  
ORCID: 0000-0001-9314-5679  
Homepage: www.antonpottegaard.dk  
Born 1986



### Education

2019 Doctor in Medical Sciences (DMSc) at University of Southern Denmark  
*Thesis: Pharmacoepidemiological assessment of drug-cancer associations*

2012-2014 PhD in Pharmacoepidemiology at University of Southern Denmark  
*Thesis: Pharmacoepidemiological aspects of vitamin K antagonist treatment (main supervisor: Jesper Hallas)*

2009-2011 Master in Clinical Pharmacy at University of Southern Denmark

2006-2009 Bachelor in Pharmacy at Copenhagen University

### Occupational experience

2019-Present University of Southern Denmark, professor

2016-Present The Hospital Pharmacy at Odense University Hospital, Head of Research

2016-2019 University of Southern Denmark, associate professor

2011-2017 Copenhagen Sønderbro Pharmacy, project pharmacist

2014-2016 University of Southern Denmark, PostDoc

2011-2014 University of Southern Denmark, PhD-student

2012-2013 Capital Region Pharmacy, project manager

2011 Danish Medicines Agency, Institute for Rational Pharmacotherapy, project employee

### Academic commissions of trust

2022 (planned) Host of the 2022 International Conference for the International Society for Pharmacoepidemiology to be held in Copenhagen, Denmark

2020-Present Chair of Social Media subcommittee within International Society for Pharmacoepidemiology

2020 Project lead appointed by Danish Medicines Agency on large-scale academic-regulator collaboration (DACCOWID) performing pharmacoepidemiological analyses to support Danish and international regulatory decision-making during the covid-19 pandemic

2020-2021 Co-chair of International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Research Review Committee for the 2021 ISPOR Online Conference

2020-2021 Co-chair of ISPE-ISPOR Special Task Force on harmonization of research protocols

2020-2021 Member of ISPE Real-World-Evidence Task Force

2020-2021 Member of the Core Committee planning the 2021 International Conference for International Society for Pharmacoepidemiology in Seattle, US

2019-2020 Member of the advisory group for the Danish Medicine Without Harm

2017-2019 Chair of the Education Committee at International Society for Pharmacoepidemiology

2017-Present Assistant editor for Basic and Clinical Pharmacology and Toxicology

2015 Host of the Nordic Pharmacoepidemiology Network (NorPEN) conference held in Odense, Denmark

2013-2019 Chair of the Danish Society for Pharmacoepidemiology

2013-2015 Board member of the Danish Pharmaceutical Society

2012-Present Board member at the Danish National Database of Reimbursed Prescriptions  
2012-2017 Vice chairman in the Danish Pharmaceutical Society, Section for Clinical Pharmacy

## Honors and awards

2020 BCPT Young Researcher Nordic Prize for outstanding contribution to pharmacological research  
2017 Best oral presentation at the annual meeting for the Danish Society of Pharmacology  
2015 Lundbeck Foundation Young Researcher Talent Award (100,000dkk personal award)

## Grants, research contracts and international collaborations

I have published together with 550+ researchers from all over the world (examples include US, Australia, Taiwan, Japan, South Korea, Ghana, the Scandinavian countries, UK, Germany, Holland, Spain, and Canada) and am, or have been involved in, several large-scale international collaborations either collaborator or principal investigator (PI). Further, I have successfully obtained funding from several Danish funds such as the Velux Foundation or the Danish Council for Independent Research. Finally, I serve as PI for several large-scale contracts for regulator-mandated phase IV-studies funded by the industry with funds paid to my institution.

### **Psychotropic medications and Glioma: an international pharmacoepidemiological study (2020-present)**

Role: Co-investigator (PI: Blánaid Hicks, Queens University, Belfast, Ireland)

Funding: £170,098 obtained from Cancer Research UK (2020; CRUK Prevention and Population Research Project Grant).

Project: Glioma causes significant morbidity and mortality worldwide and treatment options remain limited. With this project, we aim to set up an international multicenter study from the UK, Denmark, Sweden, Norway, and the USA, to investigate (i) the association between antidepressant use and glioma risk and (ii) the use of psychotropic medications among glioma patients.

### **Improving the quality of observational studies on drug-cancer associations (2017-present)**

Role: PI

Funding: €295,000 from the Danish Council of Independent Research (2017; Project 1, Medical Sciences)

Project: In this PhD project (Kasper B. Kristensen), we develop new insights in addressing common issues related to confounding in pharmacoepidemiological drug-cancer studies. The project is conducted in collaboration with the Danish Cancer Society, Harvard University, and Kaiser Permanente and aims to increase the overall quality of research in this field and, ultimately, drug safety.

### **Mapping attitudes towards deprescribing and developing a medication discontinuation model (2017-present)**

Role: PI

Funding: €162,000 (2017) and €215,000 (2019) from the Velux Foundation.

Project: Deprescribing is increasingly recognized as a potential solution to the increasing medication use among older people, particularly those in the last years of life. In this project, we explored patients', relatives' and health care professionals' attitudes towards deprescribing in older people with limited life expectancy in a series of systematic reviews, interview studies, and questionnaire-based studies. Based on our findings, we developed a comprehensive and patient-centered deprescribing intervention which is currently tested in a randomized clinical trial among older people with a life expectancy shorter than two years.

### **Testing interventions for discontinuation of proton pump inhibitors (2019-2021)**

Role: PI

Funding: €88,000 from Danish Region's "Medicinpuljen" (2018); €36,000 from the Region of Southern Denmark (2018).

Project: The consumption of proton pump inhibitors is extensive in Denmark as well as in the rest of the world. In this randomized controlled trial, we are testing two interventions to discontinue proton pump inhibitor treatment among patients with no solid indication for continued treatment, recruiting patients via community pharmacies.

### **Epidemiological assessment of the risk for pancreatic cancer associated with the use of semaglutide in patients with type 2 diabetes - A cohort study based on Nordic registry data (2019-2026)**

Role: PI

Budget: €1,613,000 overall budget of which €993,000 goes to the University of Southern Denmark. Funded by Novo Nordisk A/S.

Project: A potential risk of pancreatic cancer has been hypothesized for incretin mimetic class of antidiabetic drugs, including the Glucagon-like peptide-1 (GLP-1) analogues. In this regulator-mandated post-authorization safety study (PASS), we will set up an international multicenter study from Denmark, Sweden and Norway to evaluate whether exposure to semaglutide (an GLP-1 analogue) influences the risk of pancreatic cancer in patients with type 2 diabetes.

### **The Brodalumab Assessment of Hazards: A Multinational Safety Study in Electronic Healthcare Databases (2017-2031)**

Role: Co-investigator (PI: Jesper Hallas, University of Southern Denmark, Denmark)

Budget: €7,473,000 overall budget of which €4,402,000 goes to the University of Southern Denmark. Funded by LEO Pharma.

Project: Brodalumab is a new immunomodulatory antibody developed for treatment of moderate to severe plaque psoriasis in adults. In this regulator-mandated post-authorization safety study (PASS), we have set up an international multicenter study in Denmark, Sweden, Norway, the Netherlands, Germany, and Italy, to monitor potential risks associated with the use of brodalumab in the treatment of psoriasis with regards to serious infections, suicidal attempts, cardiovascular outcomes and malignancies.

### **Treatment changes with oral anticoagulants in atrial fibrillation (2016-2019)**

Role: PI

Funding: €331,000 from the Danish Council of Independent Research (2017; Project 1, Medical Sciences)

Project: In this PhD project (Maja Hellfritzsch), we described treatment changes with oral anticoagulants and clinical implications hereof. The results of the project have been published in specialist journals within pharmacology, thrombosis and hemostasis, and epidemiology.

### **Developing a screening tool for carcinogenic effects of prescription drugs (2014-2017)**

Role: PI

Funding: €345,000 from the Danish Council of Independent Research (2013; Individual postdoc, Medical Sciences)

Project: In this project, we established a system to screen for carcinogenic or chemopreventive effects of prescription drugs. The project was carried out in collaboration with the Danish Cancer Society and Harvard University. The project was successful and was published in EBioMedicine in 2016 and identified several leads for later projects, including the identification of an association between hydrochlorothiazide and risk of skin cancer, leading to several high-impact publications and worldwide regulatory action.

## **Publications and citations**

My publications currently include **255 peer-reviewed articles** (235 original articles and 20 reviews) of which I am the **primary author of 46**, second author of 59 and **last author of 73** (leaving 77 as an 'in-between' author). I have furthermore been involved in 3 editorials/commentaries, 1 case report, 11 letters, 2 book-chapters, and 100+ posters. Lastly, I have authored one full textbook in pharmacology.

My research has been published in high-ranking general journal such as Journal of the American Medical Association (JAMA), the British Medical Journal (BMJ), and JAMA Internal Medicine, as well as high-ranking specialist journals such as Gut, International Journal of Epidemiology, European Urology, Journal of the American Academy of Dermatology (JAAD), Journal of the American College of Cardiology (JACC), and many others. I have been **cited 2865 times** and I have an **H-index of 26** (source: Web of Science). Similar numbers according to Google Scholar are 4670 and 36 [Updated December 2020].

## Teaching

I am the Head of Studies for the Pharmacist education at the University of Southern Denmark. I am furthermore teaching at a wide range of courses (e.g., pharmacists and medical students and at the PhD school), in addition to being course lead for the Master's course "Evidence-based medicine" for clinical pharmacists. Finally, I am involved in numerous recurring course activities within the International Society for Pharmacoepidemiology and the Danish Society for Pharmacoepidemiology.

## Outreach and dissemination

I am convinced of the importance of curating the findings from my research, e.g. via social media where I maintain active profiles on both Twitter (1600+ followers) and LinkedIn (2000+ followers). I use these channels to promote our findings, often in the form of short videos or similar walkthroughs, as well as to engage with other researchers and organizations. In addition, I frequently publish laymen articles describing our research findings, e.g., via ScienceNordic.com, the Danish ForskerZonen or LinkedIn. Finally, I contribute actively to the public debate on use of medicines and on health science in general.

## PhD supervision

Helene Christine Kildegaard Jensen (planned 2021-, main supervisor)  
Tentative title: "Pharmacoepidemiological aspects of pediatric medicine"

Ditte Bork Iversen (2020-, co-supervisor)  
Title: "Supporting safe use of antibiotics: Penicillinase-resistant penicillins as inducers of drug metabolism and drug transport" (main supervisor: Tore B. Stage, University of Southern Denmark)

Nikolaj Mannering (2020-, co-supervisor)  
Title "On adverse outcomes in immune thrombocytopenia - a population-based cohort study" (main supervisor: Henrik Frederiksen, Odense University Hospital)

Camilla Lynnerup (2020-, co-supervisor)  
Title: "Polypharmacy and medication safety in vulnerable older migrants with cognitive disorders" (main supervisor: Dorte Nielsen, Odense University Hospital)

Alaa Hassan Burghle (2020-, main supervisor)  
Title: "Public health research in the Danish community pharmacy setting"

Stine Munk Hald (2018-, co-supervisor)  
Title: "Association of drug use with risk of intracerebral hemorrhage" (main supervisor: David Gaist, Odense University Hospital)

Lars Christian Lund (2018-, co-supervisor)

Title: “Big-data screening for undiscovered drug-outcome associations” (main supervisor: Jesper Hallas, University of Southern Denmark)

Carina Lundby Olesen (2018-2020, main supervisor)

Title: “Patients’, relatives’ and health care professionals’ attitudes towards deprescribing in older people with limited life expectancy”

Wade Thompson (2017-2020, co-supervisor)

Title: “Statins in the oldest old: clinical effectiveness and approaches to shared decision-making” (main supervisor: Dorte E. Jarbøl, University of Southern Denmark)

Kasper Bruun Kristensen (2017-, main supervisor)

Title: “Improving the quality of observational studies on drug-cancer associations”

Maja Hellfritsch Simonsen (2016-2019, main supervisor)

Title: “Switching between oral anticoagulants in atrial fibrillation”

Lotte Rasmussen (2015-2019, main supervisor)

Title: “Use of psychotropic drugs in children and adolescents with neurodevelopmental disorders”

Mathias Tiedemann Svendsen (2015-2018, co-supervisor)

Title: “Psoriasis patients’ use of topical treatment: lessons from registries, patients’ perspectives and an attempt to improve adherence” (main supervisor: Klaus Ejner Andersen, Odense University Hospital)

Sidsel Arnspang Pedersen (2015-2018, co-supervisor)

Title: “The association between hydrochlorothiazide use and risk of skin cancer” (main supervisor: David Gaist, Odense University Hospital)

Anne Broe (2015-2018, co-supervisor)

Title: “Phthalate containing drugs and human reproduction” (main supervisor: Per Damkier, Odense University Hospital)

Zandra Nymand Ennis (2015-2019, assistant supervisor)

Title: “Exposure to phthalate-containing drug products and the risk of gastrointestinal cancers” (main supervisor: Per Damkier, Odense University Hospital)

Morten Rix (2015-2018, co-supervisor)

Title: “Meta-analyses of outcome postponement in cardiological trials” (main supervisor: Jesper Hallas, University of Southern Denmark)

Mette Mørch Klemmensen Reilev (2014-2018, co-supervisor)

Title: “Epidemiological approaches towards describing treatment and course of COPD in the general population” (main supervisor: Jens Søndergaard, University of Southern Denmark)

Kristian Hallundbæk Mikkelsen (2014-2016, co-supervisor)

Title: “Are there metabolic consequences of antibiotics-induced changes in the human gut microbiota?” (main supervisor: Filip K. Knop, University of Copenhagen)

Mette Bliddal (2014-2016, co-supervisor)

Title: “Mental and musculoskeletal health according to weight and weight changes in motherhood. A follow-up in the Danish National Birth Cohort” (main supervisor: Ellen Nøhr, Odense University Hospital)

Kasper Søtoft Larsen (2013-2015, co-supervisor)

Title: “Pharmacoepidemiological aspects of allopurinol use on cardiovascular diseases among hyperuricemic individuals” (main supervisor: Jesper Hallas, University of Southern Denmark)

## **Member of PhD evaluation committee**

2020 Manon Cairat, Université de Lyon and the International Agency for Research on Cancer  
Thesis title: “Inflammation and breast cancer risk in the EPIC cohort”  
Main supervisor: Laure Dossus, Université de Lyon

Maria Keilow, Aarhus University

Thesis title: “Children’s mental health and educational opportunity – exploring socioeconomic aspects of ADHD”

Main supervisor: Carsten Obel, Aarhus University

2019 Pirathiv Kugathasan, Aalborg University

Thesis title: “Somatic morbidity and mortality in patients with schizophrenia”

Main supervisor: René Ernst Nielsen, Aalborg University

## **Responsibilities and service at University of Southern Denmark**

2020	Appointed responsibility for the transition of teaching activities to online platforms during the covid-19 pandemic at the Faculty of Health, University of Southern Denmark
2019-Present	Head of Study at the Pharmacy education, University of Southern Denmark
2017-Present	Reviewer for applications for enrollment to the PhD program at the University of Southern Denmark
2017-2019	Vice-Head of Study at the Pharmacy education, University of Southern Denmark
2016-Present	Teaching various courses at the PhD School at the Faculty of Health
2016-Present	Course lead for “Evidence-based medicine and biostatistics”, a Master’s course for pharmacy students with clinical specialization.

## **Peer-review**

### **High-ranking general journals**

New England Journal of Medicine (NEJM); British Medical Journal (BMJ); Journal of the American Medical Association (JAMA).

### **High-ranking specialist journals**

Journal of the American College of Cardiology (JACC); British Journal of Cancer; Thorax; Clinical Journal of the American Society of Nephrology (CJASN); Acta Psychiatrica Scandinavia; JAMA Pediatrics; JAMA Psychiatry.

### **Epidemiological journals**

Epidemiology; American Journal of Epidemiology; Clinical Epidemiology; Pharmacoepidemiology and Drug Safety.

### **Pharmacological journals**

British Journal of Clinical Pharmacology; European Journal of Clinical Pharmacology; Basic and Clinical Pharmacology and Toxicology; Drug Safety.

### **Other minor journals**

North American Journal of Medical Sciences; Drugs in R&D; Neuropsychiatric Disease and Treatment; Journal of Sleep Research; African Journal of Pharmacy and Pharmacology; Acta Odontologica; BMJ Open; Journal of Clinical Psychiatry; Psychopharmacology; Journal of Clinical Psychopharmacology; European Journal of Internal Medicine; Canadian Journal of Cardiology; Environmental Health; Medicine; European Journal of Hospital Pharmacy; International Journal of Clinical Pharmacy; International Journal of Cardiology; American Journal of Cardiology; Journal of The European Academy of Dermatology and Venereology; Drugs & Aging; BMC Medicine.

## **Invited presentations to conferences and meetings**

2020      **Webinar on “Personalized Medicine and Digital Biomarkers” hosted by Danish Welfare Tech and BioPeople (Online, Dec 18)**

Talk: “Personalized Medicine, input from a sceptic”

**Special Symposium on the occasion of the 20<sup>th</sup> anniversary of Drug Safety Research Unit (DSRU) Education and Training (Online, available Nov 30)**

Talk: “The Danish Health Care Registries, hypothesis-free screening, and hydrochlorothiazide”

**Annual meeting in the Danish Society for Theoretical Statistics (Online, Nov 24)**

Talk: “Danish pharmacoepidemiological studies in Covid-19 (DACCVID)”

**Webinar hosted by Danish Ministry of Foreign Affairs, Invest in Denmark and the Danish Association of the Pharmaceutical Industry (Online, Nov 18)**

Talks: “Danish healthcare registries” and “Danish pharmacoepidemiological studies in Covid-19 (DACCVID)”

**Annual meeting in the Danish Society for Pharmacoepidemiology (Online, Oct 26)**

Talk: “Danish pharmacoepidemiological studies in Covid-19 (DACCVID)”

**Annual residential course for Young Physicians (Yngre Læger) in Region of Southern Denmark (Vejle, Denmark, Feb 29)**

Talk: “Use of social media (SoMe) for science dissemination”

**Annual meeting in the Danish Society of Pharmacology (Odense, Denmark, Jan 15)**

Workshop: “Introduction to Pharmacoepidemiology”

2019      **Network meeting in the Danish Network for Research and Development of Pharmacy Practice (Copenhagen, Denmark, Nov 22)**

Talk: “Disseminate your findings!”

**Network meeting in Capital Region’s network for communication specialists (Bispebjerg, Denmark, Oct 9)**

Talk: “Responsible dissemination of research findings”

**Network meeting in PharmaDanmark’s Network for Young Researchers (Copenhagen, Denmark, May 2)**

Talk: “Disseminate your findings!”

**Webinar hosted by the International Society for Pharmacoepidemiology (Online, Feb 14)**

Talk: “Considerations for drug-cancer association studies”

**1-day conference “Hypertonie 2019” (Agaplesion Markus Krankenhaus, Frankfurt, Germany, Feb 13)**

Talk: “Use of hydrochlorothiazide and risk of skin cancer”

**Annual meeting in the Danish Society of Pharmacology (Odense, Denmark Jan 17)**

Talk: “Responsible dissemination of research findings”

Workshop: “Translational research in pharmacoepidemiology”

2018

**Galderma Nordics Dermatological Symposium (Kolding, Denmark, Oct 26-27)**

Talk: “Use of hydrochlorothiazide and risk of skin cancer”

**Meeting on ‘Responsible dissemination of research findings’ hosted by the Danish Medicines Agency and the Danish Society for Pharmacoepidemiology (Copenhagen, Denmark, Oct 10)**

Talk: “Dissemination of research findings: the case of hydrochlorothiazide and skin cancer”

**Annual meeting in the Danish Society for Hypertension (Kalundborg, Denmark, April 13-14)**

Talk: “Thiazide diuretics and skin cancer”

**Annual meeting in the Danish Society for Clinical Pharmacology (Nyborg, Denmark, April 6)**

Talk: “The impact of an in-hospital multifaceted clinical pharmacist intervention on the risk of readmission: A Randomized Clinical Trial”

2017

**Annual meeting in the Danish Society for Clinical Pharmacology (Århus, Denmark, Apr 21)**

Talk: “Screening for drug-drug interactions with anticoagulant treatment”

2016

**Nordic Conference on Real World Data (Helsinki, Finland, Nov 30)**

Talk: “The reality of real-world data in a Nordic context – Possibilities and barriers for collaboration between academia and industry”

**Evening seminar organized by PharmaDanmark (Copenhagen, Denmark, Nov 8)**

Talk: “Research in community pharmacies”

2015

**29<sup>th</sup> IGSLi Conference in the International Group For The Study of Lithium Treated Patients (Aarhus, Denmark, Sep 11)**

Talk: “Long-term lithium use and risk of renal and upper urinary tract cancer”

2014

**Annual meeting “Pharma På Tværs” (Copenhagen, Denmark, Nov 8)**

Talk: “Use of big (fat Danish) data in pharmacoepidemiology”

**43<sup>rd</sup> international symposium by the European Society for Clinical Pharmacy (Copenhagen, Denmark, Oct 23)**

Talk: “How to academize clinical pharmacy – research in community pharmacies”

2013

**Anniversary meeting for Pharma+ (Copenhagen, Denmark, May 26)**

Talk: “Treatment of ADHD in Denmark: the overview that was lost...”

**Annual meeting in the Danish Society of Pharmacology (Odense, Denmark, Jan 16)**

Talk: “Drugs used against ADHD: Two pharmacoepidemiological studies”

## **Invited external guest lectures and courses**

2020

**Internal seminar at the Department of Medical Pharmacology, Toulouse University Hospital, France (Nov 16)**

Talk: “Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study”

**Internal seminar at Brigham and Women’s Hospital and Harvard Medical School, US (Sep 22)**

Talk: “Danish pharmacoepidemiological studies in Covid-19 (DACCOVID)”

**ICPE All Access, Annual meeting in the International Society for Pharmacoepidemiology (Online, fall of 2020)**

Pre-conference course: “Introduction to pharmacoepidemiology”

Pre-conference course: “Cancer-pharmacoepidemiology”

**Meeting in the Academy for Talented Youth (Online, Aug 17)**

Talk: “Introduction to Health Research”

**Internal seminar at the Danish Medicines Council (Copenhagen, Denmark, Jan 28)**

Talk: “Pharmacoepidemiology (an introduction)”

2019

**Internal seminar at the Danish Medicines Agency (Copenhagen, Denmark, Dec 6)**

Talk: “Pharmacoepidemiology to support regulatory decision making”

**Internal seminar at Department of Clinical Pharmacology, Bispebjerg Hospital (Copenhagen, Denmark, Nov 11)**

Talk: “Drug safety monitoring using big data”

**Specialty training (“A-kursus”) for physicians in Clinical Pharmacology (Odense, Denmark, Oct 21-23)**

3-day course: “Pharmacoepidemiology”

**Annual meeting in the International Society for Pharmacoepidemiology (Philadelphia, US, Aug 23-29)**

Pre-conference course: “Introduction to pharmacoepidemiology”

Pre-conference course: “Cancer-pharmacoepidemiology”

**Courses organized by the Danish Society for Pharmacoepidemiology**

1-day course: "Basic Pharmacoepidemiology" (Odense, Denmark, Nov 19)

2-day course: "Advanced Pharmacoepidemiology" (Copenhagen, Denmark, May 5)

**Midyear meeting in the International Society for Pharmacoepidemiology (Rome, Italy, Apr 7)**

Pre-conference course: "Introduction to pharmacoepidemiology"

2018 **Internal seminar at the Danish Cancer Society (Copenhagen, Denmark, Nov 23)**

Talk: "(onco)Pharmacoepidemiology"

**Internal meeting at Department of Clinical Pharmacology, Bispebjerg Hospital (Copenhagen, Denmark, Nov 23)**

Talk: "Use of prescription drugs and risk of cancer"

**Hot Topic Webinar hosted by the Danish Society for Pharmacoepidemiology (Online, Oct 26)**

Talk: "Use of antipsychotics and risk of breast cancer: A Danish nationwide case-control study"

**Steering Committee meeting in Medicine Without Harm Denmark (Copenhagen, Denmark, Oct 24)**

Talk: "The impact of an in-hospital multifaceted clinical pharmacist intervention on the risk of readmission: A Randomized Clinical Trial"

**Midyear meeting in the International Society for Pharmacoepidemiology (Toronto, Canada, Apr 22)**

Pre-conference course: "Introduction to pharmacoepidemiology"

**Course organized by the Danish Society for Pharmacoepidemiology (Odense, Denmark, Mar 20)**

1-day course: "Basic Pharmacoepidemiology"

2017 **Internal meeting at the Section for Clinical Epidemiology, Frederiksberg Hospital (Copenhagen, Denmark, May 10)**

Talk: "Introduction to use of propensity scores"

**Midyear meeting in the International Society for Pharmacoepidemiology (London, UK, Apr 2)**

Pre-conference course: "Waiting Time Distribution – There and Back Again"

2016 **Internal meeting at the Section for Clinical Epidemiology, Frederiksberg Hospital (Copenhagen, Denmark, Oct 12)**

Talk: "Clinical Pharmacology and Pharmacy - methods tapas and oncopharmacoepidemiology"

2015 **Master's course at the University of Copenhagen (Copenhagen, Denmark, Jan 8)**

Title: "Danish Prescription Registries"

2013 **Workshop for emergency medicine researchers in Region Zealand and Region of Southern Denmark (Middelfart, Denmark, Sep 19)**

Talk: "Propensity scores and some..."

**Specialty training (“A-kursus”) for physicians in Clinical Pharmacology (Odense, Denmark, Oct 28-30)**

3-day course: “Pharmacoepidemiology”

**Afternoon seminar in Section for Clinical Pharmacy, the Danish Pharmaceutical Society (Copenhagen, Denmark, June 6th)**

Title: “Establishing projects in the community pharmacy”

**Course for clinical pharmacists at Pharmakon (Hillerød, Denmark, Aug 12)**

Title: "Treatment of ADHD in Denmark, the overview that was lost"

2012 **Evening seminar for general practitioners (Copenhagen, Denmark, October 29)**

Course title: “Clinical pharmacy in general practice”

2011 **Evening seminar for general practitioners (Copenhagen, Denmark, October 24)**

Course title: “Medication review in general practice”

## **Accepted conference presentations (orals, symposias and workshops)**

2020 **ICPE All Access, Annual meeting in the International Society for Pharmacoepidemiology (Online, fall of 2020)**

Symposium: “Drug-drug-interactions, twice the fun (or more!)”

Symposium: “Trial participants vs. real-world users of medicines: How different are they really and does it matter?”

Oral: “Danish pharmacoepidemiological studies in Covid-19 (DACCVID)”

Oral: “Use of hydrochlorothiazide and risk of uveal melanoma”

2019 **Annual meeting in the International Society for Pharmacoepidemiology (Philadelphia, US, Aug 23-29)**

Workshop: “Rare cancers (consideration for drug-cancer studies)”

Oral: “Use of SSRIs and risk of subdural hematoma“

2017 **Annual meeting in the International Society for Pharmacoepidemiology (Montreal, Canada, Aug 25-31)**

Symposium: “A practical guide to implementing Sequence Symmetry Analysis; A tool for conducting studies in the Asian Pharmacoepidemiology Network (AsPEN)”

Symposium: “Improving screening of adverse drug events in large electronic healthcare databases”

Oral: “Use of hydrochlorothiazide and risk of skin cancer”

Oral: “Association of antithrombotic drug use with subdural hematoma risk”

**Annual meeting in the Danish Society of Pharmacology (Odense, Denmark, Jan 18)**

Oral: “Use of hydrochlorothiazide and risk of skin cancer”

2015 **Annual meeting in the Nordic Pharmacoepidemiological Networks (NorPEN) (Odense, Denmark, November 13-14)**

Oral: “Screening for carcinogenic or chemopreventive effects of prescription drugs”

Oral: "Long-term lithium therapy and risk of renal and upper urinary tract cancer"

**Annual meeting in the International Society for Pharmacoepidemiology (Boston, US, Aug 23-27)**

Oral: "Long-term lithium therapy and risk of renal and upper urinary tract cancer"

2014 **Annual meeting in the Danish Society for Pharmacoepidemiology (Odense, Denmark, Apr 10)**

Oral: "Use of GLP-1 analogues in Denmark"

2013 **Annual meeting in the Danish Society for Pharmacoepidemiology (Copenhagen, Denmark, Sep 23)**

Oral: "Children's relative age in class and stimulant drug use for ADHD: A Danish nationwide study"

2012 **Annual meeting in the Danish Society for Pharmacoepidemiology (Copenhagen, Denmark, Mar 7)**

Oral: "Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study"